Clinical Trials (Low Dose Naltrexone) LDN Research Trust

Condition

Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer

Condition: Cancer, Carcinoma

What Do Primary Care Providers and Nurses Need to Know About Managing Chronic Pain?

Condition: Pain

Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients

Condition: Autoimmune, Cancer, Coronavirus, Covid-19, Encephalopathy, Immune

Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain

Condition: Pain

Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone

Condition: MS, Multiple Sclerosis, Pain

Improvement in Hailey-Hailey disease with a combination of low-dose naltrexone and oral magnesium chloride: A case report

Condition: Hailey Hailey, Hailey-Hailey, Pemphigus, Skin

Naltrexone's Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures

Condition: Cancer, Carcinoma

[Met 5]-enkephalin preserves diffusion metrics in EAE mice

Condition: MS, Multiple Sclerosis

Use of low-dose naltrexone in the management of chronic pain conditions A systematic review

Condition: Pain

Background

The authors aimed to evaluate the efficacy of low-dose naltrexone in the management of chronic pain conditions and determine its potential use in orofacial pain management.

Methods

A comprehensive literature review was completed in the PubMed/MEDLINE, Embase, Cumulated Index to Nursing and Allied Health Literature, Dentistry and Oral Sciences Source Library databases up through June 17, 2019, using terms such as neurogenic, inflammation, naltrexone, temporomandibular, and chronic pain. The primary outcome was reduction in pain intensity and, secondarily, improvement in quality of life.

Results

A total of 793 studies were obtained with the initial search and 8 articles were selected for evaluation. Of these 8 articles, 4 were case reports, 3 were clinical studies, and 1 was a randomized controlled trial. Six studies included data on fibromyalgia, 2 studies included data on chronic regional pain syndrome, and 1 examined multiple diagnoses, including fibromyalgia, interstitial cystitis, and chronic pelvic pain. The primary outcome of all of the studies was pain intensity reduction.

Conclusions and Practical Implications

Low-dose naltrexone provides an alternative in medical management of chronic pain disorders as a novel anti-inflammatory and immunomodulator. It can offer additional management options, as orofacial pain conditions share characteristics with other chronic pain disorders. Owing to the size and heterogeneity of the studies, more large-scale studies are needed, along with additional studies assessing orofacial pain response to low-dose naltrexone.

Low-dose naltrexone rescues inflammation and insulin resistance associated with hyperinsulinemia

Condition: Diabetes, Obesity

Survey-reported medication changes among older adults during the SARS-CoV-2 (COVID-19) pandemic

Condition: Coronavirus, Covid-19, General, Medications

No change in the consumption of thyroid hormones after starting low dose naltrexone (LDN): a quasi-experimental before-after study

Condition: Autoimmune, Endocrine, Thyroid

Intranasal Low-Dose Naltrexone Against Opioid Side Effects: A Preclinical Study

Condition: Opiod

Naltrexone a potential therapeutic candidate for COVID-19

Condition: General

Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management

Condition: Opiod, Pain, Substance Use

Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review

Condition: Fibromyalgia, Pain

Vulvar Hailey-Hailey disease treated with low-dose naltrexone: case report and literature review

Condition: Hailey Hailey, Hailey-Hailey, Pemphigus

Abuse Liability, Anti-Nociceptive, and Discriminative Stimulus Properties of IBNtxA

Condition: Opiod, Substance Use

Low-Dose Naltrexone Reverses Facial Mechanical Allodynia in a Rat Model of Trigeminal Neuralgia

Condition: Neuropathy, Pain

Sjogren's Syndrome and Clinical Benefits of Low-Dose Naltrexone Therapy: Additional Case Reports

Condition: Autoimmune, Dry Eye, Fatigue, Pain, Sjogren's Syndrome

Synergistic PXT3003 Therapy Uncouples Neuromuscular Function From Dysmyelination in Male Charcot-Marie-Tooth Disease Type 1A (CMT1A) Rats

Condition: Charcot Marie Tooth, Charcot-Marie-Tooth

Low-dose Naltrexone Inhibits the Epithelial-Mesenchymal Transition of Cervical Cancer Cells in Vitro and Effects Indirectly on Tumor-Associated Macrophages in Vivo

Condition: Cancer, Carcinoma, Opiod

Efficacy of Low Dose Naltrexone in Psoriasis

Condition: Psoriasis, Skin

The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris; a randomized controlled clinical trial

Condition: Autoimmune, Lichen, Skin

Erythromelalgia in a Patient with Mast Cell Activation Syndrome: Response to Low Dose Naltrexone

Condition: Mast Cell Activation Syndrome, MCAS, Pain, Skin

Anticonvulsant Effects of Thalidomide on Pentylenetetrazole-Induced Seizure in Mice: A Role for Opioidergic and Nitrergic Transmissions

Condition: Opiod, Seizure

129 Medication Assisted Treatment Protocol

Condition: Opiod, Pain, Substance Use

Low-dose Naltrexone Therapy for Psoriasis

Condition: Autoimmune, Psoriasis, Skin

Transition of Patients With Opioid Use Disorder From Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens

Condition: Opiod, Pain

Naltrexone Hydrochloride 1.5-mg and 4.5-mg Capsules

Condition: Complex Regional Pain Syndrome, CRPS, Fibromyalgia, Pain, Psoriasis

Low-Dose Naltrexone: An Inexpensive Medicine for Many Ills?

Condition: Autoimmune, CFS, Chronic Fatigue Syndrome, Depression, Epilepsy, Fatigue, Fibromyalgia, IBD, Inflammatory Bowel Disease, ME, ME/CFS, Mental Health, MS, Multiple Sclerosis, Myalgic Encephalomyelitis, Opiod, Pain, RA, Rheumatoid, Rheumatoid arthritis

Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway.

Condition: Cancer, Carcinoma, Colon

Low‐dose naltrexone in Hailey–Hailey disease: the importance of dosing

Condition: Hailey Hailey, Hailey-Hailey, Pemphigus, Skin

Low-Dose Naltrexone for the Treatment of Fibromyalgia: Investigation of Dose-Response Relationships

Condition: Fibromyalgia

Enkephalin Therapy Improves Relapsing-Remitting Multiple Sclerosis

Condition: MS, Multiple Sclerosis

Low-dose Naltrexone as a Treatment for Chronic Fatigue Syndrome

Condition: CFS, Chronic Fatigue Syndrome, Crohn’s

Low-Dose Naltrexone Reduces Symptoms in Stiff-Person Syndrome

Condition: Anxiety, Depression, Mental Health, Pain, Stiff Person

Improvement of Hailey-Hailey Disease With Low-Dose Naltrexone

Condition: Hailey Hailey, Hailey-Hailey, Pemphigus, Skin

The Lowdown on Low-Dose Naltrexone

Condition: Dermatitis, Hailey Hailey, Hailey-Hailey, Lichen, Pemphigus, Pruritus, Psoriasis, Skin

Opioid-induced Hypogonadism: Pathophysiology, Clinical and Therapeutics Review

Condition: Endocrine, Hormone, Opiod, Pain

The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune response

Condition: Cancer, Carcinoma

Very Low Dose Naltrexone in Opioid Detoxification: A Double-Blind, Randomized Clinical Trial of Efficacy and Safety

Condition: Opiod, Substance Use, Ultra low dose naltrexone